CA-CEPTON/ALP.LAB
22.2.2021 14:02:12 CET | Business Wire | Press release
Cepton, a leading provider of intelligent, lidar-based solutions, and the Austrian Industry and Testing Alliance ALP.Lab have partnered to build lidar-equipped testing environments for studying complicated road driving situations. For the first time in Austria, this project will deliver real-world traffic data from complex urban and rural alpine intersections.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005304/en/
As an alliance of automotive suppliers such as Magna and AVL, and as a partner to scientific organizations like Virtual Vehicle Research, Joanneum Research and Graz University of Technology, ALP.Lab delivers real-life data on complex traffic situations to test the capabilities of the autonomous driving systems, and helps enable solutions to reduce accidents and improve traffic flows.
From narrow, foggy streets covered in snow, to cyclists overtaking a tram in the middle of an intersection, Austria, with its mountainous landscape, sees varied road driving scenarios and faces unique challenges in ensuring vehicle and pedestrian safety. Difficult traffic scenarios could pose obstacles for the seamless deployment of autonomous mobility solutions. Compiling a realistic database of different driving scenarios is, therefore, pivotal to the testing and verification of advanced driver assistance systems (ADAS) and autonomous vehicles (AVs), to ensure that they work well in complex environments.
Through this new partnership, ALP.Lab has deployed Cepton’s Helius™ Smart Lidar System to capture real-time, 3D traffic data to support the training of artificial intelligence (AI) algorithms used for the scenario-based testing of ADAS and AV features. Additionally, the collected data will make it possible to predict vehicle trajectories at intersections and enable traffic data analysis for traffic flow optimization.
As part of the Helius system, a number of Vista®-P60 lidar sensors from Cepton have been installed at the corners of road intersections and traffic roundabouts, complementing other sensor types including radar and other types of optical sensors. For traffic monitoring and analysis applications, lidars perform well in many critical cases where other sensor types struggle. Lidars offer 24/7 availability thanks to their superior perception capabilities in various lighting conditions, such as night-time, shadows and the glare of strong headlights. Lidars also offer much higher angular resolution compared to radars and minimize false negatives and false positives. The Vista-P60 lidars, powered by Cepton’s patented Micro Motion Technology (MMT®), offer a high detection range of 200 m at 30% reflectivity and an angular resolution of 0.25°, making it possible to accurately detect each arriving and departing vehicle and pedestrian at a distance of up to ~170 meters around the intersections.
The advanced Helius perception software adds an additional layer of intelligence to the lidar data from the Vista-P60. Helius takes the point cloud data from a connected network of Vista-P60 sensors and delivers real-time, 3D information on object dimensions, locations and velocities. This enables Helius to accurately track and classify the different objects involved in a traffic situation. As Helius and the other sensors used by ALP.Lab only capture anonymized data, it protects the privacy of pedestrians and vehicles while feeding ALP.Lab rich traffic data for deeper analysis.
The Helius Smart Lidar system offers optimal ease of integration. The rotation-free, mirrorless and frictionless design makes Vista-P60 sensors very durable and embeddable. The rugged sensor housing is designed to withstand harsh outdoor environments and cold climates, resulting in product robustness and longevity to drive down maintenance costs. With the pre-installed Helius software running on an edge computer, which connects a scalable network of lidar sensors, Helius is a truly plug-and-play system that is extremely easy to set up and scale up.
“We primarily selected Cepton's lidar solutions because of their durability and precise detection capabilities even at high vehicle speeds. With the information the lidar sensors provide, our data is as close to real-life as it gets. Therefore, we are able to create enhanced simulation and AV testing environments as well as detailed analyses of the traffic flow,” said Christian Schwarzl, Director of Testing and Validation from ALP.Lab. “There is amazing synergy between Cepton and ALP.Lab, as we share the same goal of making ADAS and AV features available to the mass market and to improve the safety of vulnerable road users.”
“Lidar plays a crucial role in the future of autonomous mobility, by not only serving as the 'eyes' of vehicles but also bringing intelligence to the traffic infrastructure supporting safe autonomy. In order to make ADAS and AV capabilities available to the broader public, it is crucial to gather information on traffic scenarios that all vehicles are likely to be confronted with, in order to generate proper testing environments and ensure safer roads,” said Dr. Jun Pei, CEO of Cepton. “So, we are excited to partner with ALP.Lab in this endeavor, and we are gratified that our technology can contribute significantly to its success.”
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT®-based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in Germany, Canada, Japan and India, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
About ALP.Lab
ALP.Lab is the Austrian Light Vehicle Proving Region for Automated Driving and provides comprehensive services for safe and secure testing of automated driving technologies.
Founded in 2017, ALP.Lab provides an integrated test chain for automated driving functions and vehicles, enabling testing activities in both the virtual and real world. ALP.Lab offers a holistic traffic monitoring solution to create testing scenarios out of real-life driving behavior in primary, secondary, and urban road networks. Further, ALP.Lab provides a professional testing team for Euro-NCAP-compliant ADAS/AD testing, including extensive testing equipment and different proving grounds. A unique mobile HIL (hardware-in-the-loop) system facilitates complex sensor testing and validation.
A strong network of industrial and scientific partners support the capabilities of ALP.Lab for safe and secure testing of any autonomous mobility solutions. Creating value for their customers by providing high-end testing facilities and real-time traffic data is the main driver for the Austrian Light Vehicle Proving Region for Automated Driving.
For more information, visit www.alp-lab.at and follow us on LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005304/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom